Meeting
2021 ASCO Annual Meeting
Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.
Authors
Hillary Sloane
Sysmex Inostics, Baltimore, MD
Hillary Sloane , Evgeny Izumchenko , Austin Mattox , Rifat Hasina , Aashay Patel , Frederick Jones , Hannah Quinn , Kirsten Keyser , Johannes Fredebohm , Frank Holtrup , Alexander T. Pearson , Everett E. Vokes , Tanguy Y. Seiwert , Daniel L. Edelstein , Ari Rosenberg , Nishant Agrawal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6048)
DOI
10.1200/JCO.2021.39.15_suppl.6048
Abstract #
6048
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.
First Author: Ari Rosenberg
Poster
2021 ASCO Annual Meeting
Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.
First Author: Ari Rosenberg
Poster
2018 ASCO Annual Meeting
PATHOS: A phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for human papillomavirus (HPV)-positive oropharyngeal cancer.
First Author: Mererid Evans
First Author: Evgeny Izumchenko